2016
Patient preferences regarding incidental genomic findings discovered during tumor profiling
Yushak ML, Han G, Bouberhan S, Epstein L, DiGiovanna MP, Mougalian SS, Sanft TB, Abu-Khalaf MM, Chung GG, Stein SM, Goldberg SB, Pusztai L, Hofstatter EW. Patient preferences regarding incidental genomic findings discovered during tumor profiling. Cancer 2016, 122: 1588-1597. PMID: 26970385, DOI: 10.1002/cncr.29951.Peer-Reviewed Original ResearchConceptsIncidental findingTumor profilingGermline variantsAmbulatory oncology clinicsMajority of patientsStandard of careTumor profiling testsOncology clinicPreventable diseaseFamily historyPatient tumorsInformation patientsPreventable illnessPatientsDisease variablesUnpreventable diseaseUncertain significanceDisclosure preferencesCancerFrequent concernTumorsIllnessProfiling testsDiseaseCurrent study
2015
Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States
Mougalian SS, Soulos PR, Killelea BK, Lannin DR, Abu-Khalaf MM, DiGiovanna MP, Sanft TB, Pusztai L, Gross CP, Chagpar AB. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer 2015, 121: 2544-2552. PMID: 25902916, DOI: 10.1002/cncr.29348.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapyNAC useBreast cancerStage INational Cancer Data BaseStage III breast cancerStage IIIC cancerStage II diseaseStage III diseaseAdvanced breast cancerStandard of careLow-stage cancersLogistic regression analysisChi-square testIIIC cancersStage IIIAStage IIIBAdvanced cancerAfrican American individualsStage cancerPatterns of usePatientsAcademic centersClinical advantagesMultivariate analysis
2009
Impact of Progression during Neoadjuvant Chemotherapy on Operative Management of Breast Cancer.
Caudle A, Gonzalez-Angulo A, Hunt K, Kuerer H, Pusztai L, Kau S, Mittendorf E, Hortobagyi G, Meric-Bernstam F. Impact of Progression during Neoadjuvant Chemotherapy on Operative Management of Breast Cancer. Cancer Research 2009, 69: 1090-1090. DOI: 10.1158/0008-5472.sabcs-09-1090.Peer-Reviewed Original ResearchBreast-conserving therapyNeoadjuvant chemotherapyStable diseaseFirst regimenOperative managementDisease progressionBreast cancerSecond regimenMulti-disciplinary team membersImpact of progressionSecond chemotherapy regimenAdvanced breast cancerEarly-stage diseaseStandard of careBCT candidatesClinical lymphadenopathyUnderwent mastectomyChemotherapy regimenChemotherapy regimensLocal progressionStage diseaseFurther therapyClinicopathologic dataDistant metastasisMedical oncologists
2006
The new staging classification: is it useful for clinicians? S Eva Singletary
Pusztai L. The new staging classification: is it useful for clinicians? S Eva Singletary. 2006, 79-92. DOI: 10.1201/b13912-6.Peer-Reviewed Original Research
2005
Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
Esteva FJ, Pusztai L. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale. Oncology 2005, 19: 5-16. PMID: 19364051.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBreast NeoplasmsCell ProliferationCombined Modality TherapyDisease ProgressionDrug Resistance, NeoplasmErbB ReceptorsFemaleGenetic TherapyHSP90 Heat-Shock ProteinsHumansProtein Kinase InhibitorsReceptor, ErbB-2TrastuzumabConceptsAnti-HER2 therapyHER2-positive breast cancerBreast cancerEpidermal growth factor receptor HER2Small molecule tyrosine kinase inhibitorsGrowth factor receptor HER2Common chemotherapy regimensSuppression of HER2Anti-HER2 agentsHER2-positive cancersStandard of careOverexpression of HER2Use of therapiesTyrosine kinase inhibitorsHER2 blockersChemotherapy regimensSequential regimensRandomized trialsMaximum antitumor effectMechanisms of resistanceClinical trialsOptimizing outcomesAntitumor effectsReceptor HER2HER2 activity